[Evaluation of early response to antiangiogenic treatment with dynamic contrast enhanced ultrasound]

Early functional imaging evaluation of targeted treatments in oncology is of major importance. Dynamic contrast enhanced US is now recognized as a functional imaging technique able to evaluate new antiangiogenic drugs targeting superficial and deep seated lesions. This evaluation is based on an analysis of the curve of signal intensity over time after injection of the contrast agent. The availability of quantification software allows objective quantification of tumor perfusion parameters from linear raw data, prior to logarithmic signal compression, including maximum intensity of enhancement, mean transit time, time to peak, and wash-in slope coefficient. Dynamic contrast enhanced US, a sensitive, reproducible and readily available technique, allows early prediction of tumor response to treatment based on changes in vascularity, before morphological changes (RECIST) become apparent.